



## Research in Vaccine Epidemiology: Immunogenicity, Effectiveness, and Safety

Guest Editors:

**Dr. Francesco Paolo Bianchi**

Department of Biological  
Sciences and Human Oncology,  
University of Bari, Bari, Italy

**Prof. Dr. Silvio Tafuri**

Department of Biomedical  
Science and Human Oncology,  
Aldo Moro University of Bari,  
Piazza Giulio Cesare 11, 70124  
Bari, Italy

Deadline for manuscript  
submissions:

**28 November 2024**

### Message from the Guest Editors

Vaccines have saved millions of lives and have increased the quality of life of the entire world, reducing the risk of hospitalization and impairment due to infectious diseases, showing a high efficacy, safety, and cost-effectiveness.

In the COVID-19 pandemic era, the attention of national and international public health institutions is almost entirely focused on the management and control of SARS-COV-2, especially in the first pandemic wave, which was characterized by a slowdown in the health services provided to citizens, including vaccinations.

This Special issue is focused on the recent scientific and technical progresses made in this field. We want to collect contributions about the safety, effectiveness, and immunogenicity of vaccinations used in the “real world” in order to have a complete overview of the “vaccination in the real life”.

Based on your extensive knowledge and experience, we invite you to contribute with an original report, original observation, or review, highlighting the topics described above.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)